Literature DB >> 21924635

Detection of right ventricular insufficiency and guidance of volume therapy are facilitated by simultaneous monitoring of static and functional preload parameters.

Hans Peter Richter1, Christian Petersen, Alwin E Goetz, Daniel A Reuter, Jens C Kubitz.   

Abstract

OBJECTIVE: Acute right ventricular failure (RVF) is a life-threatening condition. This study investigated whether the combination of central venous pressure (CVP) and left ventricular functional preload parameters, such as stroke volume variation (SVV) and pulse pressure variation (PPV), can be used for the detection of acute RVF and for guidance of volume therapy. DESIGN AND
SETTING: Experimental study in a university laboratory. PARTICIPANTS: Fifteen anesthetized and ventilated pigs.
MEASUREMENTS AND MAIN RESULTS: For the induction of RVF, mean pulmonary artery pressure (MPAP) was increased by 50% with a continuous infusion of a thromboxane-A(2) analog (U46619). Then, blood removal (300 mL) and retransfusion (blood 200 mL + colloid solution 200 mL) were performed. An analysis of volume responders and nonresponders was implemented. Increasing MPAP (25.1 to 37.4 mmHg) led to decreases in mean arterial pressure (72.2 to 60.1 mmHg) and cardiac output (2.8 to 2.3 L/min, p < 0.05). CVP (11.3 to 12.6 mmHg), PPV (13% to 17%), and SVV (11 to 14%) increased significantly (p < 0.05). During volume removal, MPAP (37.4 to 34.1 mmHg), mean arterial pressure (60.1 to 53.2 mmHg), and cardiac output (2.3 to 2.1 L/min) decreased (p < 0.05), whereas PPV and SVV remained unchanged. During volume loading, CVP increased in volume responders and nonresponders; however, PPV decreased in responders only.
CONCLUSIONS: Increases of CVP and SVV or PPV are suspicious for RVF. However, SVV and PPV fail to predict volume responsiveness in RVF. Changes in SVV and PPV during a volume-loading maneuver can be used to assess volume responsiveness.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924635     DOI: 10.1053/j.jvca.2011.07.016

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  7 in total

Review 1.  [Goal-directed hemodynamic therapy: Concepts, indications and risks].

Authors:  S A Haas; B Saugel; C J Trepte; D A Reuter
Journal:  Anaesthesist       Date:  2015-07       Impact factor: 1.041

2.  What's new: the management of acute right ventricular decompensation of chronic pulmonary hypertension.

Authors:  Mohammad Dalabih; Franz Rischard; Jarrod M Mosier
Journal:  Intensive Care Med       Date:  2014-09-03       Impact factor: 17.440

Review 3.  Functional hemodynamic monitoring.

Authors:  Michael R Pinsky
Journal:  Crit Care Clin       Date:  2015-01       Impact factor: 3.598

4.  Short-term independent mortality risk factors in patients with cirrhosis undergoing cardiac surgery.

Authors:  Juan Carlos Lopez-Delgado; Francisco Esteve; Casimiro Javierre; Xose Perez; Herminia Torrado; Maria L Carrio; David Rodríguez-Castro; Elisabet Farrero; Josep Lluís Ventura
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-12-12

Review 5.  Perioperative fluid management in kidney transplantation: a black box.

Authors:  Maria Helena Calixto Fernandes; Thomas Schricker; Sheldon Magder; Roupen Hatzakorzian
Journal:  Crit Care       Date:  2018-01-25       Impact factor: 9.097

6.  Pulmonary hypertension attenuates the dynamic preload indicators increase during experimental hypovolemia.

Authors:  Juan P Bouchacourt; Juan Riva; Juan C Grignola
Journal:  BMC Anesthesiol       Date:  2017-03-03       Impact factor: 2.217

7.  The PIEPEAR Workflow: A Critical Care Ultrasound Based 7-Step Approach as a Standard Procedure to Manage Patients with Acute Cardiorespiratory Compromise, with Two Example Cases Presented.

Authors:  Wanhong Yin; Yi Li; Shouping Wang; Xueying Zeng; Yao Qin; Xiaoting Wang; Yangong Chao; Lina Zhang; Yan Kang; Chinese Critical Ultrasound Study Group Ccusg
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.